To enhance the effectiveness of treatment, a versatileNP was proposed for targeted and efficient treatment of melanoma.It consisted of chemotherapeutic agent trametinib-loaded PLGA NPscoated with a biological membrane that expressed a melanoma-specificanti-gp100/HLA-A2 TCR (19LF6) (Figure 3). Here, PMEL is linked to melanoma.